The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
NU HLDGS LTD | ORD SHS CL A | G6683N103 | 13,842,186 | 1,909,267 | SH | SOLE | 1,909,267 | 0 | 0 | ||
ISHARES TR | CORE S&P500 ET | 464287200 | 60,355,528 | 140,548 | SH | SOLE | 140,548 | 0 | 0 | ||
AKERO THERAPEUTICS INC | COM | 00973Y108 | 5,251,013 | 103,816 | SH | SOLE | 103,816 | 0 | 0 | ||
89BIO INC | COM | 282559103 | 1,953,407 | 126,516 | SH | SOLE | 126,516 | 0 | 0 | ||
MADRIGAL PHARMACEUTICALS INC | COM | 558868105 | 5,861,023 | 40,133 | SH | SOLE | 40,133 | 0 | 0 |